OrPha Swiss

Summary of the Risk Management Plan (RMP)

for

BESREMI® (Ropeginterferon alfa-2b)

Solution for injection in pre-filled pen

RMP Version number CH2.0
Data lock point 14-Feb-2022 – Date final 30-Mar-2023
MAH: OrPha Swiss GmbH, 8700 Küsnacht
Date: 31.05.2023

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of Besremi is a concise document and does not claim to be exhaustive.

As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of Besremi in Switzerland is the "Arzneimittelinformation/ Information sur le médicament" (see www.swissmedic.ch) approved and authorized by Swissmedic. OrPha Swiss GmbH is fully responsible for the accuracy and correctness of the content of the published summary RMP of Besremi.

Part VI: Summary of the risk management plan

Summary of risk management plan for Besremi® (ropeginterferon alfa-2b)

This is a summary of the risk management plan (RMP) for Besremi®. The RMP details important risks of Besremi®, how these risks can be minimised, and how more information will be obtained about Besremi®'s risks and uncertainties (missing information).

Besremi®'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Besremi® should be used.

This summary of the RMP for Besremi® should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Besremi®'s RMP.

I. The medicine and what it is used for

Besremi® is authorised for treatment of Polycythaemia Vera without symptomatic splenomegaly (see SmPC for the full indication). It contains Pegylated-Proline-Interferon alfa-2b as the active substance and it is given subcutaneously by pre-filled pen with 250 µg or 500 µg ropeginterferon alfa-2b.

Further information about the evaluation of Besremi®'s benefits can be found in Besremi®'s EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage https://www.ema.europa.eu/en/medicines/human/EPAR/Besremi®.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Besremi®, together with measures to minimise such risks for learning more about Besremi®'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Besremi® is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Besremi® are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Besremi®. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Hepatotoxicity
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

Important identified risk: Hepatotoxicity	
Evidence for linking the risk to the medicine	Hepatotoxicity has been identified as a risk associated with IFN alfa use. Hepatotoxicity such as increase in gamma-glutamyl transferase, alanine aminotransferase and aspartate aminotransferase or hepatic failure was reported with IFN alfa treatment.
Risk factors and risk groups	Determination of drug induced liver injury includes an individual susceptibility. This susceptibility is governed by genetic, pre-existing and environmental factors. Predisposing factors consist of ethnicity, CYP polymorphisms, concomitant liver diseases, age, nutritional status and diet, gender and pregnancy (Tarantino *et al.*, 2009)**Fehler! Verweisquelle konnte nicht gefunden werden.**.
Risk minimisation measures	<u>Routine risk minimisation measures:</u> • SmPC sections "Dosage/Administration", "Contraindications", "Warnings and precautions", "Undesirable effects", "Pharmacokinetics" • PL sections "When should Besremi not be used?", "When should you use Besremi with caution?" "What side effects may Besremi cause?" • Legal status: Prescription only medicine (POM) <u>Additional risk minimisation measures:</u> • None

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Besremi®.

II.C.2 Other studies in post-authorisation development plan

Non-interventional Post-authorisation Safety Study: Besremi-PASS

The objective of the study is to provide further data to characterize the safety and tolerability of ropeginterferon alfa-2b by monitoring the hepatic and cardiovascular safety in patients with polycythaemia vera treated with ropeginterferon alfa-2b in routine post-authorisation use.